NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $7,108 | -11.2% | 3,145 | +23.8% | 0.00% | – |
| Q3 2022 | $8,000 | 0.0% | 2,540 | +20.2% | 0.00% | – |
| Q2 2022 | $8,000 | +60.0% | 2,114 | +722.6% | 0.00% | – |
| Q3 2021 | $5,000 | +400.0% | 257 | +295.4% | 0.00% | – |
| Q1 2020 | $1,000 | -66.7% | 65 | -59.9% | 0.00% | – |
| Q4 2019 | $3,000 | -75.0% | 162 | -74.5% | 0.00% | – |
| Q3 2019 | $12,000 | -67.6% | 636 | -38.8% | 0.00% | – |
| Q2 2019 | $37,000 | +1133.3% | 1,040 | +1006.4% | 0.00% | – |
| Q1 2019 | $3,000 | -66.7% | 94 | -65.6% | 0.00% | – |
| Q4 2018 | $9,000 | +80.0% | 273 | +217.4% | 0.00% | – |
| Q3 2018 | $5,000 | +150.0% | 86 | +126.3% | 0.00% | – |
| Q2 2018 | $2,000 | -66.7% | 38 | -36.7% | 0.00% | – |
| Q1 2018 | $6,000 | 0.0% | 60 | -83.8% | 0.00% | – |
| Q4 2015 | $6,000 | +50.0% | 371 | +2.2% | 0.00% | – |
| Q3 2015 | $4,000 | +33.3% | 363 | +60.6% | 0.00% | – |
| Q2 2015 | $3,000 | – | 226 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |